All-Cause Mortality in Persons With HIV-HBV Co-Infection Treated for HBV in Rwanda: A Population-Based Cohort Study.

ABSTRACT: Chronic hepatitis B virus (HBV) infection increases the risk of cirrhosis, hepatocellular carcinoma and non-liver complications. HIV co-infection accelerates disease progression and increases mortality risk compared to HBV mono-infection, but its impact among treated individuals is not well documented in Sub-Saharan Africa. We evaluated all-cause mortality among people with chronic HBV on treatment and assessed the effect of HIV/HBV co-infection. A retrospective cohort study using data from Rwanda's District Health Information System 2 included individuals aged ≥ 2 years treated for HBV between January 2016 and June 2022. Follow-up began 12 months after treatment initiation until death or 30 June 2023. Crude mortality rates were calculated, and multilevel Cox proportional hazards regressio

SUBMITTER: Makuza JD 

PROVIDER: S-EPMC12926269 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature